Adalimumab: new indication. Severe Crohn's disease: a second TNF alpha antagonist, subcutaneous administration.
出版信息
Prescrire Int. 2008 Aug;17(96):137.
PMID:19480092
Abstract
摘要
相似文献
1
Adalimumab: new indication. Severe Crohn's disease: a second TNF alpha antagonist, subcutaneous administration.
Prescrire Int. 2008 Aug;17(96):137.
2
Adalimumab: new indication. A last resort for treating plaque psoriasis: just another TNF alpha antagonist.
Prescrire Int. 2008 Dec;17(98):240.
3
Infliximab: new indication. Severe Crohn's disease in children: many unknowns.
Prescrire Int. 2008 Aug;17(96):145.
4
[Therapy of chronic inflammatory bowel diseases. TNF-alpha blocker in Crohn disease: earlier use is rewarding].
MMW Fortschr Med. 2008 Dec 11;150(51-52):54-5.
5
Abatacept: new drug. Rheumatoid arthritis: after failure of TNF alpha antagonists and rituximab.
Prescrire Int. 2008 Dec;17(98):232.
6
[Adalimumab for the treatment of Crohn's disease - consensus paper of the Working Group "chronic inflammatory bowel diseases" of the Austrian Society for Gastroenterology and Hepatology].
Z Gastroenterol. 2009 Apr;47(4):372-80. doi: 10.1055/s-0028-1109218. Epub 2009 Apr 8.
7
[When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?].
Tidsskr Nor Laegeforen. 2007 Jun 14;127(12):1673.
8
Closing fistulas in Crohn's disease--should the accent be on maintenance or safety?
N Engl J Med. 2004 Feb 26;350(9):934-6. doi: 10.1056/NEJMe048001.
9
[Top-down versus Step-Up: new strategies in the treatment of Crohn's disease].
Z Gastroenterol. 2009 Feb;47(2):240-2. doi: 10.1055/s-0028-1109073. Epub 2009 Feb 5.
10
Anti-TNF antibody in Crohn's disease--status of information, comments and recommendations of an international working group.
Z Gastroenterol. 1999 Jun;37(6):509-12.
Zotero 插件